Canine CA15-3 antibody and antigen (recombinant protein)

 Download 

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-CAN-CA15-3-Ag01	Recombinant Canine CA15-3 protein	3090
GMP-CAN-CA15-3-Ab01	Anti-Canine CA15-3 mouse monoclonal antibody (mAb)	1953
GMP-CAN-CA15-3-Ab02	Anti-Canine CA15-3 mouse monoclonal antibody (mAb)	1953
GMP-CAN-CA15-3-Ab03	Anti-Canine CA15-3 human monoclonal antibody (mAb)	1953
GMP-CAN-CA15-3-Ab04	Anti-Canine CA15-3 human monoclonal antibody (mAb)	1953

Size： 1mg | 10mg | 100mg

Product Description

Cat No. of Products	GMP-CAN-CA15-3-Ag01
Product Name	Recombinant Canine CA15-3 protein
Target/Biomarker	Canine Cancer antigen 15-3 ()
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Canine Cancer antigen 15-3 antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in level test of animal Dog/Canine with breast cancer.
Tag	His
Products description	Recombinant Canine CA15-3 protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-CAN-CA15-3-Ab01, GMP-CAN-CA15-3-Ab02
Product Name	Anti-Canine CA15-3 mouse monoclonal antibody (mAb)
Target/Biomarker	Canine Cancer antigen 15-3 ()
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Canine Cancer antigen 15-3 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti- antibodies in level test of animal Dog/Canine with breast cancer.
Tag	mFc
Products description	Anti-Canine CA15-3 mouse monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti- antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-CAN-CA15-3-Ab03, GMP-CAN-CA15-3-Ab04
Product Name	Anti-Canine CA15-3 human monoclonal antibody (mAb)
Target/Biomarker	Canine Cancer antigen 15-3 ()
Expression platform	CHO
Isotypes	Human IgG1
Bioactivity validation	Recombinant Canine Cancer antigen 15-3 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti- antibodies in level test of animal Dog/Canine with breast cancer.
Tag	hFc
Products description	Anti-Canine CA15-3 human monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti- antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Target/Biomarker information

Cancer Antigen 15-3 (CA15-3) is a biomarker of growing importance in the context of canine biology. Originally identified and characterized in humans, CA15-3 has since been found to have homologous counterparts in various species, including dogs. This glycoprotein plays a pivotal role in the physiology of canines, with its primary association lying in the realm of mammary tissue development and health. In female dogs, CA15-3 emerges as a key player within the intricate landscape of mammary gland physiology. The mammary glands are a crucial anatomical feature in female dogs, serving the vital function of providing nutrition to offspring during lactation. Consequently, any disturbances in mammary gland health can have far-reaching consequences for the well-being of the individual dog, particularly intact females. CA15-3 is a biomarker that exhibits dynamic expression patterns within the canine mammary glands. Its levels can vary according to physiological factors, and notable changes are observed during different stages of the reproductive cycle and lactation. This dynamic modulation is not merely incidental; it is deeply intertwined with the regulation of mammary tissue development and function. Hence, CA15-3's role as an indicator of mammary gland health extends beyond simple biomarker status—it is a critical sentinel, offering insights into the dynamic changes occurring within this tissue. Furthermore, CA15-3 in dogs is of particular interest due to its association with mammary tumors, which are relatively common in female dogs. Mammary tumors in dogs can range from benign to malignant, with varying degrees of impact on the dog's health and prognosis. CA15-3 levels have shown promise as diagnostic tools, as elevated levels often correlate with the presence of mammary tumors and their potential malignancy. This has significant implications for veterinarians and dog owners alike, as the early detection of mammary tumors can lead to timely intervention and improved treatment outcomes.

About GDU